DeepMed Research

SUN YAT-SEN MEMORIAL HOSPITAL,SUN YAT-SEN UNIVERSITY

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Camrelizumab
Drug: Apatinib
Drug: Eribulin

First Posted Date: 2020-03-11

Last Posted Date: 2023-04-12

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 46

Registration Number: NCT04303741

Locations: 🇨🇳
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳
Changhai Hospital, Navy Medical University (Second Military Medical University), Shanghai, Shanghai, China

The Function and Proteome Alteration of HDL Subclass After Aerobic Exercise

Not Applicable

Completed

Conditions: Obesity

Interventions: Behavioral: Aerobic exercise

First Posted Date: 2020-03-04

Last Posted Date: 2020-03-04

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 6

Registration Number: NCT04294238

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Capecitabine
Drug: Fulvestrant
Drug: Liposomal doxorubicin
Drug: Anastrozole
Drug: Gemcitabine
Drug: Letrozole

First Posted Date: 2020-02-06

Last Posted Date: 2020-02-10

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 760

Registration Number: NCT04258163

Locations: 🇨🇳
First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Serum Progesterone Level in HRT-FET：a RCT

Not Applicable

Conditions: Progesterone,Hormone Replacement Thawed Embryo Transfer Cycles

Interventions: Drug: intramuscular progesterone 20-40mg from D3 until pregnancy test

First Posted Date: 2020-01-30

Last Posted Date: 2020-01-30

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 423

Registration Number: NCT04248309

Vaginal Profile in IVF/ICSI and Impact on Clincal Outcome

Conditions: Vaginal Flora Imbalance

First Posted Date: 2019-12-17

Last Posted Date: 2019-12-18

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 100

Registration Number: NCT04202302

Locations: 🇨🇳
Reproductive center of Sun Yat-sen memorial hospital, Guangzhou, Guangdong, China

Effect and Safety of Apatinib on Radiation-Induced Brain Injury

Phase 2

Conditions: Radiation Injuries

Interventions: Drug: Apatinib

First Posted Date: 2019-11-05

Last Posted Date: 2019-11-05

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 36

Registration Number: NCT04152681

Locations: 🇨🇳
Yamei Tang, Guanzhou, Guangdong, China

RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Cancer
Radiation

Interventions: Radiation: regional nodal irradiation
Radiation: WBI
Radiation: chestwall XRT

First Posted Date: 2019-08-28

Last Posted Date: 2025-03-30

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 540

Registration Number: NCT04069884

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

Phase 2

Conditions: HER2-positive Breast Cancer

Interventions: Biological: KN035
Biological: Trastuzumab
Drug: Docetaxel

First Posted Date: 2019-07-26

Last Posted Date: 2019-07-26

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 59

Registration Number: NCT04034823

Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer

Phase 2

Conditions: Metastatic Breast Cancer

Interventions: Drug: Pyrotinib combined with fulvestrant

First Posted Date: 2019-07-26

Last Posted Date: 2020-12-22

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 46

Registration Number: NCT04034589

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China
🇨🇳
Sun Yat-Sen University Cancer Center, Guangyuan, China

Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）

Completed

Conditions: Radiotherapy Side Effect
Chemotherapy Effect
Oesophageal Carcinoma
Effect of Drugs
Safety Issues

Interventions: Combination Product: Neoadjuvant chemoradiotherapy
Drug: Neoadjuvant chemotherapy
Procedure: Oesophagectomy

First Posted Date: 2019-07-22

Last Posted Date: 2020-05-29

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 423

Registration Number: NCT04027543

Locations: 🇺🇸
Massachusetts General Hospital of Harvard Medical School, Boston, Massachusetts, United States
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy